Subscribe
shutterstock_1113551483_sharafmaksumov
sharafmaksumov / Shutterstock.com
12 February 2019Americas

Clarivate announces new Life Science Alliances programme

Global information company  Clarivate Analytics has launched a “Life Science Alliances Program” to provide drug and medical device developers a new way to advance their research and development.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Seven new drugs to join $1bn club by 2021, says Clarivate
21 March 2019   Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Big Pharma
Seven new drugs to join $1bn club by 2021, says Clarivate
21 March 2019   Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.

More on this story

Big Pharma
Seven new drugs to join $1bn club by 2021, says Clarivate
21 March 2019   Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB